
Anaphylaxis: Recognize & Respond Part 2: Acute Management, Prevention & the Evolving Landscape
A Practical Anaphylaxis Series: Recognize and Respond Episode 2: Acute Management, Prevention, and the Evolving Landscape
Miniseries Description:
Timely epinephrine use remains central to anaphylaxis management, yet barriers continue to delay treatment. Join host Dr. David Stukus and experts Drs. Syed Shahzad Mustafa and David B.K. Golden as they discuss epinephrine as first-line treatment, the limitations of antihistamines and corticosteroids, and available and emerging epinephrine delivery options. Explore how shared decision-making, patient education, and preparedness can support prompt treatment amid the evolving landscape of anaphylaxis.
Host: David R. Stukus, MD, FACAAI
Guests: Syed Shahzad Mustafa, MD, FACAAI, David B.K. Golden, MD, FACAAI
This episode is eligible for CME credit: Acute Management, Prevention & the Evolving Landscape
This podcast/vodcast miniseries is supported by an independent medical education grant from Aquestive Therapeutics, Inc.
Target Audience:
This activity is intended for Allergists, Advanced Practice Providers, and office staff.
Learning Objectives:
After completing this activity, participants should be better able to:
- Explain evidence-based management of anaphylaxis, including the rationale for first-line epinephrine use, barriers to timely treatment, and current U.S. and global epidemiologic trends.
Accreditation
The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation
The American College of Allergy, Asthma & Immunology (ACAAI) designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Speaker Disclosures:
David R. Stukus, MD, FACAAI Consultant: Aquestive Therapeutics, Genentech Researcher: DBV Technologies, ARS Pharmaceuticals Royalties or Patent Beneficiary: Springer Publishing
David B.K. Golden, MD, FACAAI Consultant: ARS Pharmaceuticals, Blueprint Medicine, Genentech, Novartis, Thermo Fisher Scientific, Aquestive, Celldex, Kokua, Orexo Speaker: ALK, ARS Pharmaceuticals
Syed Shahzad Mustafa, MD, FACAAI Researcher: Takeda Speaker: ARS Pharmaceuticals, AstraZeneca, Genentech, GlaxoSmithKline, Regeneron, Sanofi
Altri episodi di "AllergyTalk"



Non perdere nemmeno un episodio di “AllergyTalk”. Iscriviti all'app gratuita GetPodcast.








